Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJPE61)

Drug Name

PF-02545920 Drug Info

Synonyms

1037309-45-7; 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate; UNII-TJ5KAZ8T5G; TJ5KAZ8T5G; PF-2545920 succinate; SCHEMBL439127; CTK8C0559; DTXSID90647726; ANW-64894; AKOS016005150; KB-80291; Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1); AX8234870; TC-153639; Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt; 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Phase 2	[1]
Schizophrenia	6A20	Phase 2	[2]

Cross-matching ID

PubChem CID: 11581936
CAS Number: CAS 898562-94-2
TTD Drug ID: DMJPE61

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 10A (PDE10)	TTJW4LU	PDE10_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	5.313	4.436	5.65	5.516

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification

06 Mental, behavioural or neurodevelopmental disorder

Disease Class

ICD-11: 6A20 Schizophrenia

The Studied Tissue

Pre-frontal cortex

The Studied Disease

Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	1.99E-01	-0.07	-0.21
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	4.51E-01	-0.05	-0.32

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01939548) An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia. U.S. National Institutes of Health.